Results 51 to 60 of about 309,069 (202)

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Enhanced precision in cell culture analytics: leveraging artificial intelligence for unbiased and non-destructive assessment of cell growth and viability

Cell Death Discovery
Precise assessment of cell growth, count, and viability is a prerequisite for biological and medical research. Traditional cell analytics involve manual processes, such as cell counting or reagent-based approaches that are user-dependent and prone to ...
Cheung Pang Wong, Nasrin Khazamipour, Soroush Aalibagi, Sukrit Kapoor, Louise Ramos, Joya Maria Saade, Casper Dolleris, Janny Marie L. Peterslund, Daria Golnarian, Negin Farivar, Mads Daugaard, Nader Al Nakouzi   +11 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Effect of using different U/S probe Standoff materials in image geometry for interventional procedures : the example of prostate [PDF]

, 2011
PURPOSE: This study investigates the distortion of geometry of catheters and anatomy in acquired U/S images, caused by utilizing various stand-off materials for covering a transrectal bi-planar ultrasound probe in HDR and LDR prostate brachytherapy ...
Diamantopoulos, Stefanos, Milickovic, Natasa, Katsilieri, Zaira, Zaira Katsilieri, Vasiliki Kefala, Zogal, Pawel, Kefala, Vasiliki, Dimos Baltas, Saeed Butt, Natasa Milickovic, Butt, Saeed, Baltas, Dimos, George Sakas, Sakas, Georgios, Sakas, George, Stefanos Diamantopoulos, Pawel Zogal   +16 more
core   +1 more source

Using real world data to bridge the evidence gap left by prostate cancer screening trials

ESMO Real World Data and Digital Oncology
Background and purpose: Population-based prostate cancer screening is currently not recommended in the UK because harms may outweigh benefits. Recent changes to the diagnostic pathway have improved safety and accuracy, but uncertainty remains as to how ...
N. Norori, N. Burns-Cox, L. Blaney, N. Mayor, A. Rylance, T.T. Shah, A. Naranjo, M.D. Hobbs   +7 more
doaj   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. [PDF]

, 2009
Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a cohort of 808 patients diagnosed ...
A Gopalan, M W Kattan, Scardino, P, V Reuter, C Cooper, J Eastham, Eastham, J., Gopalan, A., Cuzick, J, Gerald, W., Gopalan, A, Reuter, V, Ambroisine, L., D M Berney, Kudahetti, S., H Moller, Scardino, P., Reuter, V., Kudahetti, S, Moller, H, Gerald, W, J Cuzick, Berney, D. M., Moller, H.; id_orcid, Møller, H., Cuzick, J., Berney, DM, L Ambroisine, Fisher, G., Eastham, J, Cooper, C., S Kudahetti, P Scardino, Ambroisine, L, Foster, C. S., Fisher, G, Foster, CS, Cooper, C, W Gerald, G Fisher, C S Foster, Kattan, M. W., Kattan, MW   +42 more
core   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Oncological outcomes of I125 low dose brachytherapy in localized prostate cancer

The Canadian Journal of Urology
Background: Low-dose rate (LDR) prostate brachytherapy is a recommended treatment of localized prostate cancer in current guidelines. The study aimed to determine biochemical relapse-free survival (BRFS) in patients treated with dynamic real-time low ...
Gilberto Chéchile Toniolo, Nuria Jornet, Jady Rojas, Natalia Tejedor, Santiago Carrara, Alicia Maccagno, Teresa Brufau   +6 more
doaj   +1 more source